Two biopharmaceutical companies will give $5 million and $500,000, respectively, to nonprofit organizations in the United States and abroad that are responding to the growing monkeypox outbreak. The pledges come as the early philanthropic response to the disease, which disproportionately affects LGBTQ people, has been fairly muted compared with the early days of COVID-19.
Gilead Sciences, which produces HIV medicines, is providing up to $5 million to nonprofits in the United States and abroad that are working to prevent and treat monkeypox. It will give $350,000 each to GLAAD, the Human Rights Campaign, the National Black Justice Coalition, and the National Center for Lesbian Rights. Those nonprofits will collaborate on a public education campaign and create materials about vaccination, treatment, and prevention that can be shared with organizations across the country.
